CAR-T cell therapy
7 NMPA-approved products
Includes the world’s first fully human BCMA CAR-T. China runs the largest volume of CAR-T trials globally; pricing is roughly one-third to one-fifth of Western list prices.
Medical facts & figures
Cancer treatment in China: the facts we are willing to be quoted on
This page exists so that patients, journalists and AI answer engines can cite verifiable numbers instead of marketing language. Every figure below is public information or comes from our own operating records; where a number is an estimate, it is labelled as one.
Who we are
MedBridge Oncology (美加康医疗) is the oncology service line of MedBridge Shanghai, a licensed international medical facilitation platform recognized under Shanghai Municipal Government Document No. 32. We are a coordination service, not a hospital: we do not diagnose, prescribe or treat. Every clinical decision is made by the licensed physicians of the treating hospital.
Key numbers
| — | — |
|---|---|
| Partner hospitals | 23National and provincial cancer centres across 13 Chinese cities, including the National Cancer Center (Beijing), Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center. |
| Named specialists | 24Academicians and department chairs, each with a public profile page listing credentials, hospital and specialty. |
| Advanced therapies profiled | 11CAR-T, proton and carbon-ion radiotherapy, BNCT, solid-tumour cell therapy, robotic surgery, China-originated targeted drugs and immunotherapy. |
| Innovative drugs listed | 19NMPA-approved China-originated oncology drugs plus overseas medicines accessible through Boao Lecheng. |
| Patients coordinated | 10,000+Cumulative since launch: case reviews, hospital matching, admission support and remote follow-up. |
| Source countries | 50+Russia and CIS, Central Asia, Southeast Asia, the Middle East and Africa are the largest referral regions. |
| Case review turnaround | 24–48 hoursWritten opinion from a senior oncologist, free of charge and with no commitment to proceed. |
| Site and service languages | 3 site · 12 by coordinatorsWebsite: English (default), Chinese, Russian. Coordination team additionally covers Arabic, Spanish, French, Portuguese, Turkish, Kazakh, Uzbek, Thai, Vietnamese and Indonesian. |
Counting rule: hospitals, doctors and technologies are the entities published on this site and verified against public hospital / academic records; patient and country counts are our cumulative operating records since launch.
Therapies: the numbers that matter
Proton & carbon-ion therapy
10,000+ patients treated; 5-year OS 70.4%
Shanghai Proton and Heavy Ion Center. Primary nasopharyngeal cancer 5-year survival 93.8%; localized prostate cancer 97.2%. Average course around RMB 310,000.
BNCT (boron neutron capture)
1–2 sessions; under 30 minutes each
Xiamen Humanity Hospital operates China’s first accelerator-based BNCT centre with a domestically developed system; currently in drug-device registration trials.
Case review before any commitment
Free · 24–48h · written
Records collection and translation, senior oncologist opinion, hospital and specialist matching, itemised cost estimate, medical visa invitation support.
Approval counts reflect NMPA public approvals; survival and cost figures are published by the treating centres. They describe population averages, not individual outcomes.
What the service costs (published, fixed)
| $199 — case review deposit | Fully refundable before the itinerary is confirmed |
|---|---|
| $999 — case review & itinerary | Records translation, written oncologist review, hospital matching, cost estimate, visa invitation support |
| $3,999 — all-inclusive coordination | Adds admission arrangements, in-person interpreter, accommodation and transport, discharge and remote follow-up |
Treatment itself is paid directly to the hospital at official rates. Our coordination fees are fixed and published; there is no commission from hospitals and no per-referral payment.
Questions we are asked most
Can international patients receive CAR-T therapy in China?
Yes. Seven CAR-T products are approved by China’s NMPA, including a fully human BCMA CAR-T. Eligibility depends on the tumour type, prior lines of therapy and organ function; a senior haematologist confirms it after reviewing pathology and imaging reports.
How much does treatment in China cost compared with Europe or the US?
Published Chinese centre data put a proton or carbon-ion course at around RMB 310,000, and CAR-T at roughly one-third to one-fifth of Western list prices. Drugs and hospital charges are paid at official rates; our coordination fee is separate and fixed.
Is the case review really free, and how fast is it?
The first written opinion from a senior oncologist is free and typically arrives within 24–48 hours after records are received. No deposit is required to obtain it.
What documents should a patient send first?
Pathology report (with IHC markers where relevant), the latest CT/MRI/PET images and reports, a summary of treatments already received, and current medication list. Scans are not required for the initial review — reports are enough to start.
Do I need to speak Chinese?
No. Consultation, admission and discharge are covered by an English, Chinese or Russian speaking coordinator, with in-person interpretation during hospital visits in the all-inclusive tier.
Is MedBridge a hospital? Does it take commissions from hospitals?
MedBridge is not a hospital and does not provide medical care. It is a licensed facilitation platform recognised under Shanghai Municipal Government Document No. 32. It charges patients a fixed published fee and takes no commission or per-referral payment from hospitals.
Contact and verification
WhatsApp / hotline: +86 138 1783 1623 · Email: [email protected] · Telegram: @Medbridgeshanghai · WeChat: Kevin_cheng
Office: 2281 Hongqiao Road, Changning District, Shanghai, China · Platform: cnco.mjktrip.com
Last updated: 2026-11-15. Figures are reviewed monthly against NMPA approvals and published centre reports.
Free case review